Trial Profile
FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Nov 2022
Price :
$35
*
At a glance
- Drugs CDX 301 (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 14 Nov 2022 Status changed from active, no longer recruiting to completed.
- 05 Nov 2021 Planned End Date changed from 6 Oct 2021 to 5 Oct 2022.
- 05 Nov 2021 Planned primary completion date changed from 6 Oct 2021 to 5 Oct 2022.